Biochemical and Biological Properties of Leukocyte Intracellular Inhibitors of Proteinases

  • M. Kopitar
  • T. Giraldi
  • P. Locnikar
  • V. Turk
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 121B)


Leukocyte proteinases are postulated to be involved in variety of physiological and pathological events (7,9). It has also been proposed that proteinases are involved in the process of malignant invasion and that they could be responsible for the altered growth control in tumor cells (14). In this context the so-called neutral proteinases — histonases are of interest. It has been suggested that the histone hydrolyzing proteinases remove histones, which are known to act as gene repressors by binding to the DNA double helix, and thus may cause the derepression which is followed by DNA synthesis and cell division (6). It has already been found that leukocyte, as well as spleen elastases and chymotrypsinlike neutral proteinases have the ability to catalyze the hydrolysis of histones (11). Relevant to this ability of neutral proteinases, proteinase inhibitors are of particular interest and many studies have appeared dealing with the effect of synthetic and protein inhibitors on neutral proteinases.


Lewis Lung Carcinoma Inhibition Ability Primary Tumor Growth 29th Annual Symposium Malignant Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anson, M. L., J. Gen. Physiol, 22 (19. 39 ) 79.Google Scholar
  2. 2.
    Astrup, T., Sixtus, T., Med. Clin. North America, 56 (1972) 153.Google Scholar
  3. 3.
    Barrett, A. J., Analyt. Biochem., 47 (1972) 280.PubMedCrossRefGoogle Scholar
  4. 4.
    Davies, B. J., Ann. N. Y. Acad. Sci., 121 (1964) 404.CrossRefGoogle Scholar
  5. 5.
    Dubin, A., Europ. J. Biochem., 73 (1977) 429.PubMedCrossRefGoogle Scholar
  6. 6.
    Fräki, J., Ruuskanen, 0., Hopsu-Havu, V. K. and Kouvalainen, K., Hoppe Seylers Z. Physiol. Chem. 354 (1973) 933.CrossRefGoogle Scholar
  7. 7.
    Fritz, H., Schiessler, A. and Geiger, R., Agents and Actions, 8 (1978) 57.PubMedCrossRefGoogle Scholar
  8. 8.
    Giraldi, T., Kopitar, M. and Sava, G., Cancer Res., 37 (1977) 3834.PubMedGoogle Scholar
  9. 9.
    Janoff, A., Blondin, J., Sandhaus, R. A., Mosser, A. and Malemud, C. In: Proteases and Biological Control (Ed. E. Reich, D. B. Rifkin and E. Shaw ), Cold Spring Harbor Laboratory, New York, (1975) 603.Google Scholar
  10. 10.
    Kopitar, M. and Lebez, D., Europ. J. Biochem., 56 (1975) 571.PubMedCrossRefGoogle Scholar
  11. 11.
    Kopitar, M., Suhar, A., Giraldi, T. and Turk, V., Acta Biol. Med. German., 36 (1978) 1872.Google Scholar
  12. 12.
    Lowry, O. H., Rosenbrough, M. J., Farr, A. L. and Randal, R. J., J. Biol. Chem., 193 (1951) 265.PubMedGoogle Scholar
  13. 13.
    Steven, F. S., Milsom, D. W. and Hunter, J. A. A., Europ. J. Biòchem., 67 (1976) 165.PubMedCrossRefGoogle Scholar
  14. 14.
    Stubblefield, E. and Brawn, R. L. In: 29th Annual Symposium of Fundamental Cancer Research, Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells. M. D. Anderson Hospital, Houston, Texas (1976).Google Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • M. Kopitar
    • 1
  • T. Giraldi
    • 2
  • P. Locnikar
    • 1
  • V. Turk
    • 1
  1. 1.Department of BiochemistryJ. Stefan InstituteLjubljanaYugoslavia
  2. 2.Istituto di FarmacologiaUniversita di TriesteItaly

Personalised recommendations